These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28404646)

  • 21. Variation in treatment strategies for the eradication of Pseudomonas aeruginosa in primary ciliary dyskinesia across European centers.
    Crowley S; Holgersen MG; Nielsen KG
    Chron Respir Dis; 2019; 16():1479972318787919. PubMed ID: 30021461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nebulized colistin for non-cystic fibrosis bronchiectasis: déjà vu all over again?
    Metersky ML; O'Donnell AE
    Am J Respir Crit Care Med; 2014 May; 189(10):1151-2. PubMed ID: 24754731
    [No Abstract]   [Full Text] [Related]  

  • 23. Severe bronchiectasis in a patient with common variable immunodeficiency.
    Viegas LP; Silva SP; Silva SL; Campos Melo A; Serra-Caetano A; Branco-Ferreira M; Azevedo P; Pereira-Santos MC; Pereira-Barbosa M
    Eur Ann Allergy Clin Immunol; 2015 May; 47(3):95-8. PubMed ID: 25951148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.
    Antonela Antoniu S
    Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1439-46. PubMed ID: 23253321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.
    Follath F; Bindschedler M; Wenk M; Frei R; Stalder H; Reber H
    Eur J Clin Microbiol; 1986 Apr; 5(2):236-40. PubMed ID: 2941289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis.
    Rayner CF; Tillotson G; Cole PJ; Wilson R
    J Antimicrob Chemother; 1994 Jul; 34(1):149-56. PubMed ID: 7961201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
    Aksamit T; De Soyza A; Bandel TJ; Criollo M; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
    Eur Respir J; 2018 Jan; 51(1):. PubMed ID: 29371384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
    Guillot E; Sermet I; Ferroni A; Chhun S; Pons G; Zahar JR; Jullien V
    Pharmacotherapy; 2010 Dec; 30(12):1252-8. PubMed ID: 21114393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study.
    Wilson R; Welte T; Polverino E; De Soyza A; Greville H; O'Donnell A; Alder J; Reimnitz P; Hampel B
    Eur Respir J; 2013 May; 41(5):1107-15. PubMed ID: 23018904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Macrolide Treatment Inhibits Pseudomonas aeruginosa Quorum Sensing in Non-Cystic Fibrosis Bronchiectasis. An Analysis from the Bronchiectasis and Low-Dose Erythromycin Study Trial.
    Burr LD; Rogers GB; Chen AC; Hamilton BR; Pool GF; Taylor SL; Venter D; Bowler SD; Biga S; McGuckin MA
    Ann Am Thorac Soc; 2016 Oct; 13(10):1697-1703. PubMed ID: 27464029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis.
    Emiralioglu N; Yalcin E; Meral A; Sener B; Dogru D; Ozcelik U; Kiper N
    J Clin Pharm Ther; 2016 Aug; 41(4):419-23. PubMed ID: 27311742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibiotic-resistant
    Gao YH; Guan WJ; Zhu YN; Chen RC; Zhang GJ
    Int J Chron Obstruct Pulmon Dis; 2018; 13():237-246. PubMed ID: 29386892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.
    Rogers GB; Bruce KD; Martin ML; Burr LD; Serisier DJ
    Lancet Respir Med; 2014 Dec; 2(12):988-96. PubMed ID: 25458200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
    Griese M; Müller I; Reinhardt D
    Eur J Med Res; 2002 Feb; 7(2):79-80. PubMed ID: 11891148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chronic bronchial infection: the problem of Pseudomonas aeruginosa].
    Cantón R; Fernández Olmos A; de la Pedrosa EG; del Campo R; Antonia Meseguer M
    Arch Bronconeumol; 2011 Jun; 47 Suppl 6():8-13. PubMed ID: 21703473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Spontaneous bilateral pneumothorax].
    Alemany Francés ML; Romero Candeira S; Fernández Aracil C
    Arch Bronconeumol; 1996 Apr; 32(4):211-2. PubMed ID: 8689024
    [No Abstract]   [Full Text] [Related]  

  • 37. Update on non-cystic fibrosis bronchiectasis.
    Bilton D
    Curr Opin Pulm Med; 2008 Nov; 14(6):595-9. PubMed ID: 18812838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis.
    Barker AF; Couch L; Fiel SB; Gotfried MH; Ilowite J; Meyer KC; O'Donnell A; Sahn SA; Smith LJ; Stewart JO; Abuan T; Tully H; Van Dalfsen J; Wells CD; Quan J
    Am J Respir Crit Care Med; 2000 Aug; 162(2 Pt 1):481-5. PubMed ID: 10934074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Randomized Controlled Trial of Atorvastatin in Patients With Bronchiectasis Infected With Pseudomonas Aeruginosa: A Proof of Concept Study.
    Bedi P; Chalmers JD; Graham C; Clarke A; Donaldson S; Doherty C; Govan JRW; Davidson DJ; Rossi AG; Hill AT
    Chest; 2017 Aug; 152(2):368-378. PubMed ID: 28554732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are ciprofloxacin dosage regimens adequate for antimicrobial efficacy and prevention of resistance? Pseudomonas aeruginosa bloodstream infection in elderly patients as a simulation case study.
    Cazaubon Y; Bourguignon L; Goutelle S; Martin O; Maire P; Ducher M
    Fundam Clin Pharmacol; 2015 Dec; 29(6):615-24. PubMed ID: 26406268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.